advertisement
PLoS ONE 21
Showing records 1 to 21 | Display all abstracts in PLoS ONE100342 Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study
Chang YH
PLoS ONE 2022; 17: e0267088
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Dias DT
PLoS ONE 2022; 17: e0268623
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Roddy GW
PLoS ONE 2022; 17: e0269261
100448 Determinants for late presentation of glaucoma among adult glaucomatous patients in University of Gondar Comprehensive Specialized Hospital. Case-control study
Belete BK; Assefa NL
PLoS ONE 2022; 17: e0267582
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Roy Chowdhury U
PLoS ONE 2022; 17: e0269261
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Almeida I
PLoS ONE 2022; 17: e0268623
100342 Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study
Chien LN
PLoS ONE 2022; 17: e0267088
100448 Determinants for late presentation of glaucoma among adult glaucomatous patients in University of Gondar Comprehensive Specialized Hospital. Case-control study
Assem AS
PLoS ONE 2022; 17: e0267582
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Ushida M
PLoS ONE 2022; 17: e0268623
100342 Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study
Chen WT
PLoS ONE 2022; 17: e0267088
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Anderson KJ; Rinkoski TA
PLoS ONE 2022; 17: e0269261
100342 Comparison of risks of arterial thromboembolic events and glaucoma with ranibizumab and aflibercept intravitreous injection: A nationwide population-based cohort study
Lin IC
PLoS ONE 2022; 17: e0267088
100448 Determinants for late presentation of glaucoma among adult glaucomatous patients in University of Gondar Comprehensive Specialized Hospital. Case-control study
Ayele FA
PLoS ONE 2022; 17: e0267582
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Lopes FS
PLoS ONE 2022; 17: e0268623
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Hann CR
PLoS ONE 2022; 17: e0269261
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Kanadani FN
PLoS ONE 2022; 17: e0268623
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Chiodo VA
PLoS ONE 2022; 17: e0269261
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Gracitelli CPB
PLoS ONE 2022; 17: e0268623
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Smith WC
PLoS ONE 2022; 17: e0269261
100712 Subtenon triamcinolone as an adjuvant in mitomycin-C-enhanced trabeculectomy in non-inflammatory glaucomas: A randomized clinical trial
Prata TS
PLoS ONE 2022; 17: e0268623
100752 Transgene expression of Stanniocalcin-1 provides sustained intraocular pressure reduction by increasing outflow facility
Fautsch MP
PLoS ONE 2022; 17: e0269261
